Mavyret approved as 8-week treatment for hep C, compensated cirrhosis
(HealthDay)—Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes 1 through 6 and compensated cirrhosis, the U.S. Food and Drug Administration announced last week. Mavyret is the first eight-week treatment approved for any treatment-naive HCV patients, regardless of cirrhosis status or […]
Continue reading »